Meta-regression regressed the standard mean differences against mean age, sex proportion, or mean Mini-Mental State Examination (MMSE) scores if at least 10 independent studies were included based on Cochrane recommendations
It remains an investigational drug currently being evaluated in Phase 3 clinical trials by Eli Lilly for the treatment of: Obesity (without diabetes) Type 2 diabetes Nonalcoholic fatty liver disease (NAFLD/NASH) Projected Approval Timeline Based on Phase 2 success and accelerated trials, Retatrutide could receive FDA approval as early as 2026 Eli Lilly is positioning it to directly compete with Tirzepatide (Mounjaro) and Semaglutide (Wegovy) Expected to be administered as a once-weekly injection Not Available for Research or Off-Label Use Retatrutide is not legally available on the gray market No legitimate research chemical suppliers offer it any listings claiming to sell Retatrutide are likely counterfeit or misbranded Because of its complex multi-receptor structure, DIY compounding is extremely risky and discouraged Athletic Use and WADA Considerations Like other GLP-1 agonists, Retatrutide is not currently banned by WADA However, its performance-enhancing effects (fat loss, appetite suppression, metabolic acceleration) could put it under scrutiny in the future Athletes in tested federations should proceed cautiously once the drug is commercialized Until Retatrutide clears regulatory approval, its use remains confined to clinical trial settings
Promising results were seen, but more study is needed
The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019
Biologic agents are usually injected either subcutaneously (under the skin) or intravenously (through a tube inserted into a vein)
0.1% TFA/ACN
